 |
  
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
New Dosing Recommendations Retrovir (Zidovudine) Syrup for HIV-Infected InfantsNovember 6, 2009 On November 6, 2009, the Food and Drug Administration (FDA) approved revised pediatric dosing recommendations that expand dosing to include children starting treatment at four weeks of age. The revised label contains the following recommendation: The recommended dosage in pediatric patients 4 weeks of age and older and weighing >4 kg is provided in Table 1. RETROVIR Syrup should be used to provide accurate dosage when whole tablets or capsules are not appropriate. Table 1: Recommended Pediatric Dosage of RETROVIR
 This article was provided by U.S. Food and Drug Administration. Visit the FDA's website to find out more about their activities and publications.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before adding your comment, please read TheBody.com's Comment Policy.) |
|
|||||||||||||||||||||||||||||
Email
Comments
Print-Friendly
Glossary
The Body: About The Body | Contact The Body | Content Policy | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
